相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
EMT, cancer stem cells and autophagy; The three main axes of metastasis
Ghader Babaei et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway
Kishan Kumar Nyati et al.
CANCER LETTERS (2021)
Microfluidic System to Analyze the Effects of Interleukin 6 on Lymphatic Breast Cancer Metastasis
Hyeon-Yeol Cho et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer
Ho Tsoi et al.
CANCERS (2021)
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
Matthew Kearney et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Nitric Oxide-Releasing Drug Glyceryl Trinitrate Targets JAK2/STAT3 Signaling, Migration and Invasion of Triple-Negative Breast Cancer Cells
Sarra Bouaouiche et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells
Ksenia Magidey-Klein et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Serum IL-6 as a vital predictor of severe lung cancer
Jian An et al.
ANNALS OF PALLIATIVE MEDICINE (2021)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?
Qiuyao Huang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
The Effect of a Newly Synthesized Ferrocene Derivative against MCF-7 Breast Cancer Cells and Spheroid Stem Cells through ROS Production and Inhibition of JAK2/STAT3 Signaling Pathway
Mitra Nourbakhsh et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2020)
Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo
Zhe Liu et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer
Li Pan et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer
Michael S. Ball et al.
SCIENTIFIC REPORTS (2020)
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis
Rasmus Siersbaek et al.
CANCER CELL (2020)
Pentadecanoic Acid, an Odd-Chain Fatty Acid, Suppresses the Stemness of MCF-7/SC Human Breast Cancer Stem-Like Cells through JAK2/STAT3 Signaling
Ngoc Bao To et al.
NUTRIENTS (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Precise discovery of a STAT3 inhibitor from Eupatorium lindleyanum and evaluation of its activity of anti-triple-negative breast cancer
Bo Yang et al.
NATURAL PRODUCT RESEARCH (2019)
Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer
Jilai Tian et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
Patricia Barrionuevo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer
Yueh-Shan Weng et al.
MOLECULAR CANCER (2019)
Dihydrotanshinone-Induced NOX5 Activation Inhibits Breast Cancer Stem Cell through the ROS/Stat3 Signaling Pathway
Su-Lim Kim et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
3-Deoxy-2β,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cells
Hui Shan et al.
ACTA PHARMACOLOGICA SINICA (2019)
Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors
Guiping Cai et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway
Qing Xie et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer
Hyejin Ko et al.
BIOMOLECULES (2019)
Inhibition of Tyrosine-Phosphorylated STAT3 in Human Breast and Lung Cancer Cells by Manuka Honey is Mediated by Selective Antagonism of the IL-6 Receptor
Priyanka Aryappalli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis
Jones Gyamfi et al.
SCIENTIFIC REPORTS (2019)
Inhibition of Stat3 Signaling Pathway by Natural Product Pectolinarigenin Attenuates Breast Cancer Metastasis
Yali Li et al.
FRONTIERS IN PHARMACOLOGY (2019)
Adjuvant therapy with stattic enriches the anti-proliferative effect of doxorubicin in human ZR-75-1 breast cancer cells via arresting cell cycle and inducing apoptosis
Fatemeh Khaki-khatib et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
Lynn J. Howie et al.
CLINICAL CANCER RESEARCH (2019)
DT-13 suppresses breast cancer metastasis by modulating PLOD2 in the adipocytes microenvironment
He Jinyong et al.
PHYTOMEDICINE (2019)
Methylseleninic Acid Suppresses Breast Cancer Growth via the JAK2/STAT3 Pathway
Changwei Qiu et al.
REPRODUCTIVE SCIENCES (2019)
Anticancer Activity of Tubulosine through Suppression of Interleukin-6-Induced Janus Kinase 2/Signal Transducer and Activation of Transcription 3 Signaling
Byung-Hak Kim et al.
JOURNAL OF BREAST CANCER (2019)
Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Juergen Wollenhaupt et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation
Zong-Lin Zhang et al.
BREAST CANCER (2018)
Interleukin-6 Family Cytokines
Stefan Rose-John
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models
An-Qi Zeng et al.
ONCOTARGET (2018)
2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells
Liang-Chih Liu et al.
ANTICANCER RESEARCH (2018)
Mechanisms of immune evasion in breast cancer
Joshua P. Bates et al.
BMC CANCER (2018)
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
Joyce O'Shaughnessy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer
Yunhui Hu et al.
CANCER LETTERS (2018)
Transcriptional repression of human epidermal growth factor receptor 2 by ClC-3 Cl-/H+ transporter inhibition in human breast cancer cells
Mayu Fujimoto et al.
CANCER SCIENCE (2018)
JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance
Tianyi Wang et al.
CELL METABOLISM (2018)
Breast cancer bone metastases: pathogenesis and therapeutic targets
Naomi Brook et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition
Eunhye Oh et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
Sven H. Loosen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells
Hauke Loecken et al.
JOURNAL OF NATURAL PRODUCTS (2018)
Catechol derived from aronia juice through lactic acid bacteria fermentation inhibits breast cancer stem cell formation via modulation Stat3/IL-6 signaling pathway
Hack Sun Choi et al.
MOLECULAR CARCINOGENESIS (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line
Hiroki Wakabayashi et al.
BREAST CANCER (2018)
Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells
Jones Gyamfi et al.
SCIENTIFIC REPORTS (2018)
GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling
Puja Khanna et al.
SCIENTIFIC REPORTS (2018)
Tagalide A and tagalol A, naturally occurring 5/6/6/6-and 5/6/6-fused cyclic dolabrane-type diterpenes: a new insight into the anti-breast cancer activity of the dolabrane scaffold
Xiao-Hui Zhang et al.
ORGANIC CHEMISTRY FRONTIERS (2018)
Bioassay-guided isolation of cantharidin from blister beetles and its anticancer activity through inhibition of epidermal growth factor receptor-mediated STAT3 and Akt pathways
Jaemoo Chun et al.
JOURNAL OF NATURAL MEDICINES (2018)
Esculentoside A suppresses breast cancer stem cell growth through stemness attenuation and apoptosis induction by blocking IL-6/STAT3 signaling pathway
Chuanlan Liu et al.
PHYTOTHERAPY RESEARCH (2018)
The molecular details of cytokine signaling via the JAK/STAT pathway
Rhiannon Morris et al.
PROTEIN SCIENCE (2018)
Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway
Yuguang Yang et al.
ONCOLOGY LETTERS (2018)
Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer
Lanyun Feng et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2018)
Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses
Larissa Lamertz et al.
SCIENCE SIGNALING (2018)
Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis
Kideok Jin et al.
BREAST CANCER RESEARCH (2018)
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
Daniel G. Stover et al.
NPJ BREAST CANCER (2018)
The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer
Mohammad W. Khan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
Sylvia Heink et al.
NATURE IMMUNOLOGY (2017)
Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer
Marcela Moises Maluf Sanguinete et al.
IMMUNOLOGICAL INVESTIGATIONS (2017)
A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-κB Activity in MDA-MB-231 Breast Cancer Cells
Dinesh Vyas et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2017)
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
P. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling
C. Lin et al.
ONCOGENE (2017)
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
Nicolino Ruperto et al.
PEDIATRIC RHEUMATOLOGY (2017)
Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study
Qi Wu et al.
ONCOTARGET (2017)
Tocilizumab (Actemra)
Martin Sheppard et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Interlekukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Supressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer
Mengmeng Jiang et al.
FRONTIERS IN IMMUNOLOGY (2017)
IL-6 variant is associated with metastasis in breast cancer patients
Chike O. Abana et al.
PLOS ONE (2017)
Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista
Wei Shi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway
Naoya Yamashita et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy
Rashmi Bharti et al.
CANCER LETTERS (2017)
STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis
Laura M. Jones et al.
CANCER RESEARCH (2016)
ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Rα from the cell surface of leukocytes during inflammatory responses
Isabell Yan et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer
R. Bharti et al.
ONCOGENE (2016)
STAT3 integrates cooperative Ras and TGF-β signals that induce Snail expression
M. Saitoh et al.
ONCOGENE (2016)
The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease
Beata Kotowicz et al.
TUMOR BIOLOGY (2016)
Interleukins 1 and 6 as main mediators of inflammation and cancer
O. S. Dmitrieva et al.
BIOCHEMISTRY-MOSCOW (2016)
IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells
Keunhee Oh et al.
BMC CANCER (2016)
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study
Andre Hennigs et al.
BMC CANCER (2016)
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors
Haihong Zhong et al.
CANCER RESEARCH (2016)
A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice
Xiaoqian Wang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis
Jie Yang et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer
Vivian Labovsky et al.
TUMOR BIOLOGY (2016)
Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts
Beatriz Morancho et al.
ONCOTARGET (2016)
Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models
Adam R. Wolfe et al.
ONCOTARGET (2016)
Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17
Steffen Riethmueller et al.
SCIENTIFIC REPORTS (2016)
Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-ocpositive breast cancer
Tineke Casneuf et al.
BREAST CANCER-TARGETS AND THERAPY (2016)
Impact of breast cancer subtypes and patterns of metastasis on outcome
Karin Kast et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
Albert Deisseroth et al.
CLINICAL CANCER RESEARCH (2015)
Interleukin-6: Biology, signaling and strategies of blockade
Fred Schaper et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2(+) breast cancers
Ruth Rodriguez-Barrueco et al.
GENES & DEVELOPMENT (2015)
Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells
Fei Zhang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels
Tomofumi Miura et al.
PANCREAS (2015)
Interleukin-6 and pro inflammatory status in the breast tumor microenvironment
Alessandro Sanguinetti et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2015)
Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model
F. Yang et al.
CELL DEATH & DISEASE (2015)
Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells
Hsueh-Te Lee et al.
ONCOTARGET (2015)
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer
Jessica M. Baron et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
Association Between Ligands and Receptors Related to the Progression of Early Breast Cancer in Tumor Epithelial and Stromal Cells
Vivian Labovsky et al.
Clinical Breast Cancer (2014)
STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits
Seyung S. Chung et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Drug Design Targeting Protein-Protein Interactions (PPIs) Using Multiple Ligand Simultaneous Docking (MLSD) and Drug Repositioning: Discovery of Raloxifene and Bazedoxifene as Novel Inhibitors of IL-6/GP130 Interface
Huameng Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
IL-6 trans-Signaling-Dependent Rapid Development of Cytotoxic CD8+ T Cell Function
Jan P. Boettcher et al.
CELL REPORTS (2014)
STAT3 Target Genes Relevant to Human Cancers
Richard L. Carpenter et al.
CANCERS (2014)
Soluble Interleukin-6 Receptor is a Prognostic Marker for Relapse-Free Survival in Estrogen Receptor-Positive Breast Cancer
Hye Sung Won et al.
CANCER INVESTIGATION (2013)
Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy
Chin Hao Chang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
Miao-Fen Chen et al.
MOLECULAR CANCER (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
Rajeshwari Mehta et al.
PLOS ONE (2013)
The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis
Qing Chang et al.
NEOPLASIA (2013)
Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer
Bozena Dobrzycka et al.
EUROPEAN CYTOKINE NETWORK (2013)
IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures
Guozhu Xie et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+Breast Cancer by Expanding the Cancer Stem Cell Population
Hasan Korkaya et al.
MOLECULAR CELL (2012)
The composition and signaling of the IL-35 receptor are unconventional
Lauren W. Collison et al.
NATURE IMMUNOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Athena Chalaris et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2011)
The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor α and Cyclin D1
Joan S. Lewis-Wambi et al.
MOLECULAR PHARMACOLOGY (2011)
A Perspective on Cancer Cell Metastasis
Christine L. Chaffer et al.
SCIENCE (2011)
FDA approves tocilizumab to treat rheumatoid arthritis
Cheryl A. Thompson
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2010)
A novel small-molecule inhibitor of IL-6 signalling
Giovanna Zinzalla et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells
Li Lin et al.
CANCER RESEARCH (2010)
Constitutively Active Stat3 Enhances Neu-Mediated Migration and Metastasis in Mammary Tumors via Upregulation of Cten
Isaia Barbieri et al.
CANCER RESEARCH (2010)
Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells
Joomin Lee et al.
CARCINOGENESIS (2010)
Interleukin-6 in bone metastasis and cancer progression
Tasnim Ara et al.
EUROPEAN JOURNAL OF CANCER (2010)
Analysis of the Effect of Serum Interleukin-6 (IL-6) and Soluble IL-6 Receptor Levels on Survival of Patients with Colorectal Cancer
Kun-Yun Yeh et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Naphtho[1,2-b]furan-4,5-dione disrupts Janus kinase-2 and induces apoptosis in breast cancer MDA-MB-231 cells
Kuei-Li Lin et al.
TOXICOLOGY IN VITRO (2010)
A Novel Small Molecule, LLL12, Inhibits STAT3 Phosphorylation and Activities and Exhibits Potent Growth-Suppressive Activity in Human Cancer Cells
Li Lin et al.
NEOPLASIA (2010)
CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells
Zhenfeng Duan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer
Angela DeMichele et al.
CANCER RESEARCH (2009)
An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation
Dimitrios Iliopoulos et al.
CELL (2009)
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
Victor G. Vogel
Expert Review of Anticancer Therapy (2009)
Serum interleukin-6 and-10 levels in patients with gastric cancer
Masahide Ikeguchi et al.
GASTRIC CANCER (2009)
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
N. J. Sullivan et al.
ONCOGENE (2009)
Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells
M. Walter et al.
ONCOGENE (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
STAT3 can be activated through paracrine signaling in breast epithelial cells
Jacqueline C. Lieblein et al.
BMC CANCER (2008)
Fibroblasts Isolated from Common Sites of Breast Cancer Metastasis Enhance Cancer Cell Growth Rates and Invasiveness in an Interleukin-6-Dependent Manner
Adam W. Studebaker et al.
CANCER RESEARCH (2008)
Role of Stat3 in suppressing anti-tumor immunity
Marcin Kortylewski et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Raloxifene in breast cancer prevention
Luigi Gennari et al.
EXPERT OPINION ON DRUG SAFETY (2008)
Protein tyrosine phosphatases in the JAK/STAT pathway
Dan Xu et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice
Maciej Kujawski et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2
Qin Ryan et al.
ONCOLOGIST (2008)
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland
Pasquale Sansone et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression
Hui-Wen Lo et al.
CANCER RESEARCH (2007)
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity
Khandaker Siddiquee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer
Marjan Berishaj et al.
BREAST CANCER RESEARCH (2007)
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Stattic: A small-molecule inhibitor of STAT3 activation and dimerization
Jochen Schust et al.
CHEMISTRY & BIOLOGY (2006)
Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory t cells
HH Oberg et al.
INTERNATIONAL IMMUNOLOGY (2006)
Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3
K Leslie et al.
CANCER RESEARCH (2006)
An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer
ZK Sun et al.
IMMUNOBIOLOGY (2006)
Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation
S Haan et al.
CELLULAR SIGNALLING (2005)
Evaluation of potential Stat3-regulated genes in human breast cancer
FC Hsieh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
RM McLoughlin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors
JV Alvarez et al.
CANCER RESEARCH (2005)
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells
H Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy
H Bozcuk et al.
CYTOKINE (2004)
Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C
TN Dechow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
TH Wang et al.
NATURE MEDICINE (2004)
Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer
V Michalaki et al.
BRITISH JOURNAL OF CANCER (2004)
Serum interleukin-6 levels reflect the disease status of colorectal cancer
YC Chung et al.
JOURNAL OF SURGICAL ONCOLOGY (2003)
Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex
MJ Boulanger et al.
SCIENCE (2003)
Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells
L Yang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
T Bachelot et al.
BRITISH JOURNAL OF CANCER (2003)
Circulating interleukin-6 predicts survival in patients with metastatic breast cancer
R Salgado et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Suppressors of cytokine signaling and immunity
M Kubo et al.
NATURE IMMUNOLOGY (2003)
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice
A Katsume et al.
CYTOKINE (2002)
Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells
PJ Real et al.
ONCOGENE (2002)
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
GL Niu et al.
ONCOGENE (2002)
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
WM Burke et al.
ONCOGENE (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses
T Jostock et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status
XP Jiang et al.
CYTOKINE (2000)
分享论文
